BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11495817)

  • 1. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
    Guilhot F
    Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
    [No Abstract]   [Full Text] [Related]  

  • 2. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
    Etienne G; Mahon FX
    Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ
    Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract]   [Full Text] [Related]  

  • 4. New-age drug meets resistance.
    McCormick F
    Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
    [No Abstract]   [Full Text] [Related]  

  • 5. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib and chronic-phase leukemias.
    Boros LG; Lee WN; Cascante M
    N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman JM; Melo JV
    N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 12. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glivec and CML: a lucky date.
    Saglio G; Cilloni D; Rancati F; Boano L
    J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J
    Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].
    López-Karpovitch X
    Rev Invest Clin; 2003; 55(2):191-5. PubMed ID: 12827926
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
    Shah NP; Sawyers CL
    Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
    Joensuu H
    Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
    [No Abstract]   [Full Text] [Related]  

  • 19. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Hochhaus A
    Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
    Joensuu H; Roberts PJ; Sarlomo-Rikala M; Andersson LC; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri GD
    N Engl J Med; 2001 Apr; 344(14):1052-6. PubMed ID: 11287975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.